Hematologic malignancies and other marrow failure states: progress in the management of complicating infections.
D000380:Agranulocytosis / Q000139:chemically induced / Q000150:complications; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000209:etiology; D003428:Cross Infection; D064420:Drug-Related Side Effects and Adverse Reactions; D005334:Fever / Q000209:etiology; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000628:therapy; D007275:Injections, Intravenous / Q000009:adverse effects; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D009181:Mycoses / Q000188:drug therapy; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000209:etiology; D018805:Sepsis / Q000209:etiology; D013203:Staphylococcal Infections / Q000209:etiology; D014123:Toxoplasmosis / Q000188:drug therapy; D014611:Vaccination; D014777:Virus Diseases / Q000188:drug therapy / Q000209:etiology
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents